CAR-T Cell Therapy: Advances in Kidney-Related Diseases

Abstract

Currently, renal malignancies and some diseases accompanied by renal impairment, such as multiple myeloma (MM), systemic lupus erythematosus (SLE), and acquired immunodeficiency syndrome (AIDS) are characterized by encouraging benefits from immunotherapy that have led to significantly improved outcomes. In this regard, the chimeric antigen receptor (CAR)-T represents a further step forward in the field of immunotherapy, which is becoming a hot issue and revealing potential in these diseases. Additionally, with numerous novel targets and indications being discovered and tried for clinical practice, the nephrotoxicity associated with CAR-T cell therapy also needs attention. In this review, we focused on discussing the effects and drawbacks of CAR-T cell therapy in several common diseases involving kidneys, as well as how we might enhance it.